An Open Label, Single-dose, Single-period Study to Assess the Pharmacokinetics, Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-XEN1101 in Healthy Male Subjects
Latest Information Update: 18 Jan 2022
At a glance
- Drugs Encukalner (Primary)
- Indications Partial epilepsies
- Focus Pharmacokinetics
- Sponsors Xenon Pharmaceuticals
- 13 Jan 2022 Status changed from recruiting to completed.
- 14 Sep 2021 Status changed from not yet recruiting to recruiting.
- 12 Jul 2021 New trial record